Spinal muscular atrophy type 3 (SMA type 3) is a hereditary disease characterized by progressive atrophy of skeletal muscles, which leads to impaired motor function. The main cause of this disease is the lack of a specific protein, smutin, which is necessary for the functioning of motor neurons in the spinal cord. Clinically, SMA type 3 usually manifests itself in childhood or adolescence, when patients begin to notice difficulties in moving, muscle weakness, and fatigue during physical activity. This chronic but slowly progressive disease can significantly reduce the quality of life, although most patients retain the ability to move independently.
History of the disease and interesting historical facts
The first stage of studying spinal muscular atrophy dates back to the end of the 19th century, when in 1891 the French physician Jules Jeténéa defined spinal muscular atrophy as a separate disease. However, it was not until 1956 that it was established that SMA is caused by genetic mutations. In 1995, the SMN1 gene responsible for the production of smuthin was identified, which was a significant breakthrough in understanding the mechanism of the disease. Given the progress in genetics, in the last two decades, scientists have focused on developing new treatments, including gene therapy, which opens up new horizons for patients suffering from this form of atrophy.
Epidemiology
Spinal muscular atrophy type 3 has a fairly high prevalence among hereditary diseases, especially among the white population. It is taken into account that its frequency is approximately 1 in 6,000-10,000 newborns. Statistics show that with one carrier of the SMN1 gene, the probability of having a child with SMA type 3 is 25%. According to various population studies, this disease manifests itself in both sexes with equal frequency, but depending on the genetic background, some ethnic groups may demonstrate higher rates.
Genetic predisposition to this disease
Spinal muscular atrophy type 3 is caused by mutations in the SMN1 gene, which is located on chromosome 5. There are different types of mutations, including deletions, point mutations, and other genetic changes. The presence of a mutation in at least one SMN1 allele is required for the disease to manifest, but most cases are characterized by homozygous mutations. Research has also found that specific mutations can occur in breeding groups, highlighting the complexity of inheritance and the variety of manifestations of this disease.
Risk factors for the development of this disease
Spinal muscular atrophy type 3 is mostly a hereditary disease and the risk factors for this condition are limited. The main risk factors include:
- Heredity - the presence of parents who are carriers of the SMN1 gene.
- Genetic predisposition - the presence of other diseases associated with abnormalities in the genes of spinal muscular atrophy.
- Ethnic groups - some populations have a higher frequency of inherited genetic mutations.
It is important to note that, unlike other diseases, the influence of external physical or chemical factors on the risk of developing spinal muscular atrophy has not been established.
Diagnosis of this disease
Diagnosis of spinal muscular atrophy type 3 is based on a comprehensive analysis of the clinical picture, laboratory tests and radiological examinations. The main symptoms to pay attention to include:
- Muscle weakness, especially in the lower limbs.
- Impaired coordination of movements.
- Difficulty walking or standing.
Laboratory tests include genetic testing for mutations in the SMN1 gene. Radiological tests, such as MRI, may be used to rule out other diseases of the nervous system. The differential diagnosis should consider other causes of muscle weakness, including myasthenia gravis, dystrophies, and neuromuscular diseases.
Treatment
Treatment for spinal muscular atrophy type 3 consists of several components. General therapy is aimed at relieving symptoms and restoring lost functions:
- Pharmacological treatment - classical drugs such as antidepressants and muscle relaxants can be used to manage symptoms.
- Physical therapy - Regular exercise helps maintain muscle strength and coordination.
- Surgical treatment is possible in cases where correction of skeletal anomalies is necessary.
- Gene therapies - New treatments such as Zolgensma are gaining attention due to their ability to deliver an active SMN1 gene.
Treatment requires an individual approach and should be carried out taking into account the patient's condition.
List of medications used to treat this disease
Several medications are currently used to treat spinal muscular atrophy type 3, including:
- Nusinersen (Spinraza) - modifies SMN2 mRNA splicing, increasing smutin levels.
- Zolgensma is a one-time gene therapy that replaces the defective SMN1 gene.
- Risdiplam is an oral drug that also aims to improve smuthin production.
These drugs can significantly improve the functional status of patients.
Disease monitoring
Monitoring of patients with spinal muscular atrophy type 3 should include regular examinations and assessment of disease progress. Control steps should include:
- Regular examination for changes in muscle strength and function.
- Evaluation of pulmonary ventilation and respiratory system functions.
- Psychological support and social conditions for patients and their families.
Prognosis depends on the severity of the disease and the quality of timely medical care. Possible complications may include respiratory infections and postural disorders, which makes regular monitoring extremely important.
Age-related features of the disease
Spinal muscular atrophy type 3 most often appears in childhood or adolescence. In children, the disease is characterized by either motor delays or decreased strength in the limbs. Unlike more severe forms of SMA, the disease can progress slowly, with most patients reaching adulthood. However, additional mobility and health problems may arise in later years. Adult patients may suffer from chronic fatigue and a gradual loss of muscle strength as the disease progresses.
Questions and Answers
- What are the main symptoms of spinal muscular atrophy type 3? The main symptoms include muscle weakness, especially in the lower limbs, difficulty with coordination, and fatigue with physical activity.
- How is spinal muscular atrophy type 3 diagnosed? Diagnosis involves clinical evaluation, genetic testing for mutations in the SMN1 gene, and exclusion of other diseases with similar symptoms.
- Is there an effective treatment for this disease? Yes, new treatments such as gene therapy have greatly improved the condition of patients. In addition, physical therapy and medications are used to relieve symptoms.
- What is the prognostic guarantee for patients with spinal muscular atrophy type 3? The prognosis depends on the perception of the disease, but most patients are able to maintain their mobility and quality of life for many years.
- What do you need to know about supporting patients with SMA type 3? It is important to provide a comprehensive approach, including physical rehabilitation, psychological support and impact on the social needs of the patient and his family.
